Natural killer cell therapy with standard maintenance treatment for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This trial tests adding natural killer (NK) cells to your usual maintenance treatment for advanced solid tumors. NK cells are a type of immune cell that may help your body fight cancer more effectively and delay the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have one of the following cancers that cannot be removed by surgery or has spread: non-small cell lung cancer (without certain genetic mutations), colorectal, liver, or gastric / gastroesophageal junction cancer.
- You have already completed a standard first-line treatment course (4–6 or 6–9 cycles depending on cancer type) and your scans show the cancer is stable, smaller, or gone.
- You have not taken any other experimental cell therapy before.
- You are in generally good health (able to care for yourself), with adequate bone marrow, liver, and kidney function.
- You are willing to use reliable contraception during the study and for at least 6 months after the last infusion if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies an experimental cell therapy called NK510 for people with advanced stomach or colorectal cancer that has not responded to standard treatments. The therapy uses natural killer cells, a type of immune cell, to attack the cancer. It may help slow or stop the cancer's growth.
This trial tests a new treatment using natural killer (NK) cells, a type of immune cell, to fight advanced solid tumors. It may be an option if standard treatments have stopped working or are not available.
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
This trial tests an investigational NK cell therapy (NK042) for people with advanced solid tumors that have not responded to standard treatments. The aim is to see if this cellular therapy is safe and potentially effective.
This trial tests a new type of cell therapy (natural killer cells) made from a donor, combined with low-dose IL-15 (a protein that helps these cells work) and sometimes with pembrolizumab (Keytruda), for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests an experimental cell therapy for people with advanced solid tumors that have not responded to standard treatments. It targets tumors with specific genetic markers (KRAS or NRAS G12D and HLA-A*11:01) to see if it can shrink or slow the cancer.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.